SNP rs13194504 AA Genotype Linked to Severity of Tardive Dyskinesia
By Elana Gotkine HealthDay Reporter
TUESDAY, June 25, 2024 -- For patients with schizophrenia, the single-nucleotide polymorphism (SNP) rs13194504 AA genotype is associated with reduced severity of tardive dyskinesia (TD), but is not associated with occurrence, according to a study recently published in Human Psychopharmacology: Clinical & Experimental.
Ruoyu Wang, from the Centre for Addiction and Mental Health in Toronto, and colleagues tested SNPs rs13194504 and rs210133 for the association with the occurrence and severity of TD among 172 patients with schizophrenia who were recruited for four studies at three clinical sites in Canada and the United States.
The researchers found that there was an association for the rs13194504 AA genotype with reduced severity for TD, as measured by the Abnormal Involuntary Movement Scale (AIMS), but not for occurrence of TD. No significant association was seen for rs210133 with either TD occurrence or AIMS scores.
"Our results suggest that the SNP rs13194504 AA genotype may be associated with decreased severity of TD, thus pointing to a potential protective effect against TD," the authors write.
Several authors disclosed ties to the pharmaceutical industry.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
Source: HealthDay
Posted : 2024-06-26 03:15
Read more
- Poll Finds Most Americans Stressed Over Election, Future of Nation
- New Combo Drug Therapy Halves Death Risk From Advanced Hodgkin Lymphoma
- Progression-Free Survival Improved With Nivolumab + AVD in Hodgkin Lymphoma
- Duodenal ReCET Plus Semaglutide Can Prevent Need for Insulin in T2DM
- NIH Clinical Trial Will Test Precision Medicine Treatments for Myeloid Cancers
- CDC Confirms Second Human Bird Flu Case in Missouri With No Known Exposure to Farm Animals
Disclaimer
Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.
The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.
Popular Keywords
- metformin obat apa
- alahan panjang
- glimepiride obat apa
- takikardia adalah
- erau ernie
- pradiabetes
- besar88
- atrofi adalah
- kutu anjing
- trakeostomi
- mayzent pi
- enbrel auto injector not working
- enbrel interactions
- lenvima life expectancy
- leqvio pi
- what is lenvima
- lenvima pi
- empagliflozin-linagliptin
- encourage foundation for enbrel
- qulipta drug interactions